<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02558517</url>
  </required_header>
  <id_info>
    <org_study_id>medint002</org_study_id>
    <nct_id>NCT02558517</nct_id>
  </id_info>
  <brief_title>Evaluation of the Discontinuation of Maintenance Corticosteroid Treatment in Quiescent Systemic Lupus</brief_title>
  <acronym>CORTICOLUP</acronym>
  <official_title>Evaluation of the Discontinuation of Maintenance Corticosteroid Treatment (Prednisone 5 Milligram Per Day) in Quiescent Systemic Lupus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Groupe Hospitalier Pitie-Salpetriere</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Groupe Hospitalier Pitie-Salpetriere</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Systemic Lupus (SLE) is a chronic disease for which long term treatments are warranted. The
      aim of this study was to study the possibility of corticosteroids interruption in patients
      with quiescent SLE treated since at least one year with 5 milligrams of predonisone per day.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">January 2018</completion_date>
  <primary_completion_date type="Anticipated">January 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Occurence of mild or moderate flares of SLE defined by the SLE FLARE Index</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">136</enrollment>
  <condition>Systemic Lupus Erythematosus</condition>
  <arm_group>
    <arm_group_label>Prednisone maintenance</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients will be kept under Prednisone 5 milligrams/day. Other treatments will be maintained (in particular HYDROXYCHLOROQUINE, METHOTEXATE etc..)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prednisone discontinuation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Prednisone will be stopped and remplaced by HYDROCORTISONE for one month (20 mg/day). Other treatments will be maintained (in particular HYDROXYCHLOROQUINE, METHOTEXATE etc..)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>prednisone discontinuation</intervention_name>
    <description>randomization</description>
    <arm_group_label>Prednisone discontinuation</arm_group_label>
    <other_name>prednisone maintenance</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with SLE according to the ACR revised criteria.

          -  Quiescent disease without flare since at least one year (SELENA SLEDAI &lt; or equal to
             4, BILAG C, D or E, PGA 0) _ Treatment with 5 milligrams/day of prednisone since at
             least 1 year

        Exclusion Criteria:

          -  failure to sign the informed consent or unable to consent

          -  Patient participating to another clinical trial

          -  Pregnancy or plan to become pregnant
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zahir AMOURA, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Groupe Hospitalier Pitié Salpêtrière</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zahir AMOURA, MD</last_name>
    <phone>+33 1 42 17 80 01</phone>
    <email>zahir.amoura@aphp.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Fleur COHEN AUBART, PD, PhD</last_name>
    <phone>+33 1 42 17 82 42</phone>
    <email>fleur.cohen@aphp.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Groupe Hospitalier Pitié Salpêtrière, Service de médecine Interne 2, Institut e3m</name>
      <address>
        <city>Paris</city>
        <zip>75 013</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zahir AMOURA, MD</last_name>
      <phone>+33 1 42 17 80 01</phone>
      <email>zahir.amoura@aphp.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 22, 2015</study_first_submitted>
  <study_first_submitted_qc>September 23, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 24, 2015</study_first_posted>
  <last_update_submitted>August 10, 2016</last_update_submitted>
  <last_update_submitted_qc>August 10, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 11, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Groupe Hospitalier Pitie-Salpetriere</investigator_affiliation>
    <investigator_full_name>Dr Cohen Aubart</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>Systemic Lupus Erythematosus</keyword>
  <keyword>Corticosteroids</keyword>
  <keyword>Chronic disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lupus Erythematosus, Systemic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Hydroxychloroquine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

